Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million.

The successful trials come after Starlink rival AST SpaceMobile also used its newly launched satellites to power a video call ...

WELL Health Technologies Corp., a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, ...

Bluebird bio (BLUE) shares continued their downward descent Monday following news that the company plans to be taken private through a deal valued at up to $96M. Read more here.

Verizon and AST have yet again pushed the boundaries of what can be done with mobile devices by successfully trialing a live ...

Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Bluebird Bio (BLUE) to $5 from $40 and keeps an Equal Weight rating on the ...

Today’s game against the Tigers has been cancelled due to inclement weather. Looks like it’s going to be raining pretty much ...

JPMorgan upgraded Bluebird Bio (BLUE) to Neutral from Underweight without a price target after the company entered into a definitive agreement ...

12 years after going public, beleaguered gene therapy company bluebird bio will be sold to private equity groups Carlyle and ...

AST SpaceMobile ( ASTS -9.45%), a producer of low earth orbit (LEO) satellites for cellular networks, saw its stock soar more ...